Hiroaki Tanioka

1.6k total citations
90 papers, 1.1k citations indexed

About

Hiroaki Tanioka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hiroaki Tanioka has authored 90 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 25 papers in Surgery. Recurrent topics in Hiroaki Tanioka's work include Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (17 papers) and Gastric Cancer Management and Outcomes (15 papers). Hiroaki Tanioka is often cited by papers focused on Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (17 papers) and Gastric Cancer Management and Outcomes (15 papers). Hiroaki Tanioka collaborates with scholars based in Japan, United States and France. Hiroaki Tanioka's co-authors include Yoshiro Takeda, Hiroyuki Hamakawa, Tomoki Sumida, Hideo Inoue, Yutaka Hashimoto, Akira Ichihara, Kenichi Sogawa, Fujio Suzuki, Yasushi Daikuhara and Yang Bao and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Biochemical and Biophysical Research Communications.

In The Last Decade

Hiroaki Tanioka

88 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroaki Tanioka Japan 20 392 309 267 197 149 90 1.1k
Dario Arzani Italy 21 283 0.7× 228 0.7× 433 1.6× 174 0.9× 95 0.6× 51 1.2k
Kazuhiko Yoshimatsu Japan 17 554 1.4× 394 1.3× 218 0.8× 298 1.5× 85 0.6× 184 1.2k
Zhuming Guo China 15 312 0.8× 221 0.7× 615 2.3× 183 0.9× 118 0.8× 98 1.4k
Kenneth Ng United States 19 469 1.2× 124 0.4× 327 1.2× 384 1.9× 133 0.9× 48 1.2k
Charles D. Haas United States 17 301 0.8× 210 0.7× 149 0.6× 285 1.4× 108 0.7× 68 915
Jesús Romero Spain 16 340 0.9× 193 0.6× 364 1.4× 335 1.7× 50 0.3× 62 1.0k
Hyun Ju Kim South Korea 16 355 0.9× 250 0.8× 299 1.1× 169 0.9× 76 0.5× 50 1.2k
Chun‐Shu Lin Taiwan 23 304 0.8× 362 1.2× 330 1.2× 371 1.9× 67 0.4× 87 1.4k
Dolores Gallardo‐Rincón Mexico 18 524 1.3× 165 0.5× 494 1.9× 275 1.4× 96 0.6× 49 1.3k
Siwei 10 490 1.3× 276 0.9× 502 1.9× 298 1.5× 98 0.7× 21 1.3k

Countries citing papers authored by Hiroaki Tanioka

Since Specialization
Citations

This map shows the geographic impact of Hiroaki Tanioka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Tanioka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Tanioka more than expected).

Fields of papers citing papers by Hiroaki Tanioka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Tanioka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Tanioka. The network helps show where Hiroaki Tanioka may publish in the future.

Co-authorship network of co-authors of Hiroaki Tanioka

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Tanioka. A scholar is included among the top collaborators of Hiroaki Tanioka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Tanioka. Hiroaki Tanioka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tanioka, Hiroaki, Yoshiko Mori, Takehiro Tanaka, et al.. (2022). Genomically Stable Gastric Cancer Characterized by Hypomethylation in Wnt Signal Cascade. Oncology. 101(2). 105–116. 3 indexed citations
3.
Inada, Ryo, Takeshi Nagasaka, Mototsugu Shimokawa, et al.. (2022). Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. European Journal of Cancer. 169. 166–178. 2 indexed citations
4.
5.
Kawai, Takashi, Yoshiko Mori, Takehiro Tanaka, et al.. (2021). Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. Clinical Epigenetics. 13(1). 117–117. 12 indexed citations
6.
Mori, Yoshiko, Hiroyuki Kishimoto, Yuzo Umeda, et al.. (2021). Concordance of Acquired Mutations between Metastatic Lesions and Liquid Biopsy in Metastatic Colorectal Cancer. Future Science OA. 7(10). FSO757–FSO757. 1 indexed citations
7.
Satake, Hironaga, Hiroki Hashida, Hiroaki Tanioka, et al.. (2021). Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases. The Oncologist. 26(7). e1125–e1132. 3 indexed citations
8.
Shinozaki, Katsunori, Takeshi Yamada, Junichiro Nasu, et al.. (2020). A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). International Journal of Clinical Oncology. 26(2). 399–408. 3 indexed citations
9.
Sunakawa, Yu, Kaoru Mogushi, Heinz‐Josef Lenz, et al.. (2018). Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics. 17(12). 2788–2795. 3 indexed citations
10.
11.
12.
Miyamoto, Yuji, Akihito Tsuji, Hiroaki Tanioka, et al.. (2016). S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). International Journal of Clinical Oncology. 21(4). 705–712. 6 indexed citations
13.
Mizushima, Takaaki, Koji Ochi, Hiroaki Tanioka, et al.. (2007). Oral administration of taurine improves experimental pancreatic fibrosis. Journal of Gastroenterology and Hepatology. 23(2). 321–327. 8 indexed citations
14.
Tanioka, Hiroaki, Takaaki Mizushima, Koji Ochi, et al.. (2005). Xanthine oxidase‐derived free radicals directly activate rat pancreatic stellate cells. Journal of Gastroenterology and Hepatology. 21(3). 537–544. 10 indexed citations
15.
Mizushima, Takaaki, Hiroaki Tanioka, Koji Ochi, et al.. (2003). Metastatic Pancreatic Malignant Melanoma: Tumor Thrombus Formed In Portal Venous System 15 Years After Initial Surgery. Pancreas. 27(2). 201–203. 14 indexed citations
16.
Sumida, Tomoki, et al.. (2000). Clinical Usefulness of Telomerase Assay for the Detection of Lymph Node Metastasis in Patients With Oral Malignancy. Archives of Pathology & Laboratory Medicine. 124(3). 398–400. 12 indexed citations
17.
Hamakawa, Hiroyuki, et al.. (1998). Mandibular malignant schwannoma with multiple spinal metastases: A case report and a review of the literature. Journal of Oral and Maxillofacial Surgery. 56(10). 1191–1196. 19 indexed citations
18.
Ito, Chizuru, Yutaka Hashimoto, Kaori Sasaki, Hiroyuki Hamakawa, & Hiroaki Tanioka. (1990). A case of lymphangioma of the tongue associated with open bite.. Japanese Journal of Oral & Maxillofacial Surgery. 36(11). 2566–2573. 1 indexed citations
19.
Kato, Hideo, et al.. (1987). Effects of Cyclic and Continuous Total Enteral Nutrition on Circadian Cortisol Rhythm. Journal of Clinical Biochemistry and Nutrition. 2(1). 83–89. 2 indexed citations
20.
Hamakawa, Hiroyuki & Hiroaki Tanioka. (1985). Immunohistochemical study on the myoepithelial cell using anti-smooth-muscle-myosin antibody.. Japanese Journal of Oral & Maxillofacial Surgery. 31(3). 408–416. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dario Arzani Breakdown of academic impact, for papers by Kazuhiko Yoshimatsu Breakdown of academic impact, for papers by Zhuming Guo Breakdown of academic impact, for papers by Kenneth Ng Breakdown of academic impact, for papers by Charles D. Haas Breakdown of academic impact, for papers by Jesús Romero Breakdown of academic impact, for papers by Hyun Ju Kim Breakdown of academic impact, for papers by Chun‐Shu Lin Breakdown of academic impact, for papers by Dolores Gallardo‐Rincón Breakdown of academic impact, for papers by Siwei
Rankless by CCL
2026